Tesamorelin

Growth Hormone Releasing Factor Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Tesamorelin is a drug in the Growth Hormone Releasing Factor Analog class catalogued in DrugCentral. It was first approved by the FDA in 2010. DrugCentral lists 1 molecular target, including GHRHR. Recorded indications include Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy.

• Drug class: Growth Hormone Releasing Factor Analog.
• Molecular targets: GHRHR (1 listed in DrugCentral).
• Indications: Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy.
• ATC code: H01AC06 (Somatropin and somatropin agonists).
• Molecular formula: C215H357N71O67S; molecular weight 5040.71 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy

Contraindications (12)

• Breastfeeding (mother)
• Diabetes mellitus
• Edema
• Hyperglycemia
• Hypopituitarism
• Injury of head
• Postsurgical Complications
• Pregnancy, function
• Primary malignant neoplasm
• Radiation Therapy of Cranium
• Respiratory insufficiency
• Transsphenoidal hypophysectomy

Mechanism & targets

• Established pharmacologic class: Growth Hormone Releasing Factor Analog

Molecular targets (1)

Target	Gene	Action	Activity
Growth hormone-releasing hormone receptor	GHRHR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2010-11-10	FDA	—	THERATECHNOLOGIES

ATC classification

ATC code	Therapeutic hierarchy
H01AC06	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Somatropin and somatropin agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product dose omission issue	324.2
Injection site bruising	85.1
Product administration error	79.2
Injection site pain	66.8
Injection site pruritus	53.9
Product preparation issue	45.0

Chemical structure

• Molecular formula: C₂₁₅H₃₅₇N₇₁O₆₇S
• Molecular weight: 5040.71 g/mol
• CAS number: 218949-48-5
• InChIKey: —
• PubChem CID: 16137828

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tesamorelin used for?

DrugCentral lists the following indications for Tesamorelin: Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy.

How does Tesamorelin work?

Its molecular targets in DrugCentral include GHRHR (agonist).

When was Tesamorelin first approved?

Tesamorelin was first approved by the FDA in 2010.

What drug class does Tesamorelin belong to?

Tesamorelin is in the Growth Hormone Releasing Factor Analog class.

What is the chemical formula of Tesamorelin?

Tesamorelin has the molecular formula C215H357N71O67S and a molecular weight of 5040.71 g/mol.

Sources

• DrugCentral drug card 4170 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1237026 — compound record and bioactivity
• PubChem CID 16137828 — chemical identifiers
• DrugBank DB08869 — drug record
• FDA UNII MQG94M5EEO — substance identity
• DailyMed: FDA labels for Tesamorelin — current prescribing information (label search)
• UniProt Q02643 (GHRHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.